Intrepida Bio is developing first-in-class mAbs against BAG3 to modulate the TME BioCentury, 22 Oct 2019 With a $9.5 million equity round, Intrepida aims to begin clinical testing by early 2021 of its first-in-class mAbs against BAG3…